BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
Cerilliant
US Army
Dow
McKinsey
Queensland Health
Argus Health
Cantor Fitzgerald

Generated: January 19, 2018

DrugPatentWatch Database Preview

CARDURA Drug Profile

« Back to Dashboard

When do Cardura patents expire, and when can generic versions of Cardura launch?

Cardura is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in CARDURA is doxazosin mesylate. There are thirteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
Drug patent expirations by year for CARDURA
Pharmacology for CARDURA
Medical Subject Heading (MeSH) Categories for CARDURA

US Patents and Regulatory Information for CARDURA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-001 Nov 2, 1990 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-004 Nov 2, 1990 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-003 Nov 2, 1990 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-002 Feb 22, 2005 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-001 Feb 22, 2005 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for CARDURA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-001 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-004 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-003 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Citi
Queensland Health
Dow
Deloitte
Johnson and Johnson
AstraZeneca
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot